Tags

Type your tag names separated by a space and hit enter

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
Expert Rev Pharmacoecon Outcomes Res. 2016 Dec; 16(6):771-779.ER

Abstract

BACKGROUND

Severity of spasticity in multiple sclerosis (MS) directly correlates with the level and cost of care required. This study assessed whether a tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray for treatment of moderate-severe MS spasticity is a cost-effective use of healthcare resources in Wales.

METHODS

A Markov model was developed to compare THC/CBD plus standard of care (SoC) treatments with SoC alone.

RESULTS

At 30 years, total incremental cost for THC/CBD plus SoC treatment was estimated at £3,836/patient (ICER: £10,891/quality-adjusted life year [QALY]). Hospital admission costs had the greatest effect on the base case ICER. Inclusion of carer cost led to incremental cost of -£33,609/patient (ICER: -£95,423/QALY).

CONCLUSIONS

The THC/CBD spray was found to be cost-effective for the treatment of spasticity in MS, and dominant, if home carer costs were included. Use of THC/CBD has the potential to generate cost savings by significantly improving the symptoms of moderate to severe MS spasticity.

Authors+Show Affiliations

a GfK , London , UK.b Health Economics Outcomes Research , Bayer plc , Newbury , UK.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

26750641

Citation

Gras, Adrien, and Julie Broughton. "A Cost-effectiveness Model for the Use of a Cannabis-derived Oromucosal Spray for the Treatment of Spasticity in Multiple Sclerosis." Expert Review of Pharmacoeconomics & Outcomes Research, vol. 16, no. 6, 2016, pp. 771-779.
Gras A, Broughton J. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):771-779.
Gras, A., & Broughton, J. (2016). A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis. Expert Review of Pharmacoeconomics & Outcomes Research, 16(6), 771-779.
Gras A, Broughton J. A Cost-effectiveness Model for the Use of a Cannabis-derived Oromucosal Spray for the Treatment of Spasticity in Multiple Sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):771-779. PubMed PMID: 26750641.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis. AU - Gras,Adrien, AU - Broughton,Julie, Y1 - 2016/02/26/ PY - 2016/1/12/pubmed PY - 2017/3/14/medline PY - 2016/1/12/entrez KW - Multiple sclerosis KW - pharmacoeconomics KW - resource utilization KW - spasticity KW - tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray KW - treatment costs SP - 771 EP - 779 JF - Expert review of pharmacoeconomics & outcomes research JO - Expert Rev Pharmacoecon Outcomes Res VL - 16 IS - 6 N2 - BACKGROUND: Severity of spasticity in multiple sclerosis (MS) directly correlates with the level and cost of care required. This study assessed whether a tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray for treatment of moderate-severe MS spasticity is a cost-effective use of healthcare resources in Wales. METHODS: A Markov model was developed to compare THC/CBD plus standard of care (SoC) treatments with SoC alone. RESULTS: At 30 years, total incremental cost for THC/CBD plus SoC treatment was estimated at £3,836/patient (ICER: £10,891/quality-adjusted life year [QALY]). Hospital admission costs had the greatest effect on the base case ICER. Inclusion of carer cost led to incremental cost of -£33,609/patient (ICER: -£95,423/QALY). CONCLUSIONS: The THC/CBD spray was found to be cost-effective for the treatment of spasticity in MS, and dominant, if home carer costs were included. Use of THC/CBD has the potential to generate cost savings by significantly improving the symptoms of moderate to severe MS spasticity. SN - 1744-8379 UR - https://www.unboundmedicine.com/medline/citation/26750641/A_cost_effectiveness_model_for_the_use_of_a_cannabis_derived_oromucosal_spray_for_the_treatment_of_spasticity_in_multiple_sclerosis_ L2 - http://www.tandfonline.com/doi/full/10.1586/14737167.2016.1140574 DB - PRIME DP - Unbound Medicine ER -